Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1995 Apr;50(4):333–338. doi: 10.1136/thx.50.4.333

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

P L Shah 1, S F Scott 1, H J Fuchs 1, D M Geddes 1, M E Hodson 1
PMCID: PMC474268  PMID: 7785003

Abstract

BACKGROUND--A phase II multicentre double blind placebo controlled study in 1993 showed that short term treatment (10 days) with recombinant human DNase I (rhDNase) was safe and improved pulmonary function in patients with cystic fibrosis with stable stage lung disease. A six month open label treatment study was conducted in some of the patients who participated in the short term study to assess the medium term effects of rhDNase. METHODS--Patients who completed the phase II study and were stable for 14 days prior to treatment were eligible. They were treated with rhDNase 2.5 mg twice daily for six months and reviewed at regular intervals to assess safety and efficacy. RESULTS--Fifty nine patients (31M,28F) of age range 16-55 years were recruited. Mean baseline values for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were 41.5% and 72.4% of predicted, respectively. The mean increase in FEV1 over the first month of treatment was 13.1% (range 12-14.1%) and then stabilised at 6.2% (4.6-7.8%) for the subsequent five months. FVC was similarly improved. Administration of rhDNase improved the severity of dyspnoea, cystic fibrosis related symptoms, and the modified Taussig/NIH score (not statistically significant). Fifty seven of the 59 patients completed the study; two died from progression of their pulmonary disease unrelated to treatment with rhDNase. The adverse events and intercurrent illnesses were no different from those expected in a cystic fibrosis population. Pharyngitis was the only possible drug related adverse event which occurred at least once in 14% of patients during the six month period. CONCLUSIONS--Administration of rhDNase was safe, well tolerated, and improved pulmonary function in patients with cystic fibrosis. When rhDNase was stopped at day 169 there was a deterioration in pulmonary function and dyspnoea score.

Full text

PDF
333

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed] [Google Scholar]
  2. CHERNICK W. S., BARBERO G. J. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959 Nov;24:739–745. [PubMed] [Google Scholar]
  3. Dodge J. A., Morison S., Lewis P. A., Colest E. C., Geddes D., Russell G., Jackson A. D., Bentley B. Cystic fibrosis in the United Kingdom, 1968-1988: incidence, population and survival. Paediatr Perinat Epidemiol. 1993 Apr;7(2):157–166. doi: 10.1111/j.1365-3016.1993.tb00390.x. [DOI] [PubMed] [Google Scholar]
  4. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  5. Gift A. G. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs. 1989 Nov-Dec;14(6):323–325. doi: 10.1002/j.2048-7940.1989.tb01129.x. [DOI] [PubMed] [Google Scholar]
  6. Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
  7. Lethem M. I., James S. L., Marriott C., Burke J. F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990 Jan;3(1):19–23. [PubMed] [Google Scholar]
  8. Lethem M. I., James S. L., Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis. 1990 Nov;142(5):1053–1058. doi: 10.1164/ajrccm/142.5.1053. [DOI] [PubMed] [Google Scholar]
  9. Penketh A. R., Wise A., Mearns M. B., Hodson M. E., Batten J. C. Cystic fibrosis in adolescents and adults. Thorax. 1987 Jul;42(7):526–532. doi: 10.1136/thx.42.7.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ramsey B. W., Astley S. J., Aitken M. L., Burke W., Colin A. A., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Schidlow D. V. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul;148(1):145–151. doi: 10.1164/ajrccm/148.1.145. [DOI] [PubMed] [Google Scholar]
  11. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
  12. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968 Oct;98(4):697–698. doi: 10.1164/arrd.1968.98.4.697. [DOI] [PubMed] [Google Scholar]
  13. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Taussig L. M., Kattwinkel J., Friedewald W. T., Di Sant'Agnese P. A. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr. 1973 Mar;82(3):380–390. doi: 10.1016/s0022-3476(73)80110-6. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES